Zymeworks Inc. (ZYME) stock

ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30141% above fair value

$26.47−2.60 (-8.94%)

Close on Nov 12, 2026Market cap $1.88BP/E 50.9Yield –

Zymeworks EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Zymeworks's EV/EBITDA was 2.2× on Jan 31, 2024.

Period	Period end	Value	Change (pts)
2024	Jan 31, 2024	2.2×	+0.1
2023	Dec 29, 2023	2.0×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ZYME.

Revenue growth97.8% · median 23.3%

Operating margin16.6% · median -61.2%

Net margin16.3% · median -58.8%

Advertisement
300 × 250

See a number that looks wrong?